Gilead Sciences: Yeztugo And Trodelvy Make This A Buy Once More

Gilead Sciences (GILD) has been upgraded to 'Buy' from 'Hold', driven primarily by the FDA approval of YEZTUGO, a twice-yearly HIV PrEP injection, which is anticipated to significantly strengthen its dominant HIV franchise and extend its market longevity. This key development, alongside promising expansion opportunities for its oncology drug TRODELVY and a valuation currently priced for pessimistic ~0% revenue growth, suggests substantial upside potential if GILD can achieve low-to-mid single-digit revenue growth. Despite ongoing headwinds in its Liver Disease and Cell Therapy portfolios, the company maintains robust financial health with strong free cash flow and a sustainable dividend.

Analysis

Gilead Sciences (GILD) presents a compelling investment case following its upgrade to 'Buy', driven by a significant strategic development and a valuation that appears to price in excessive pessimism. The core catalyst is the recent FDA approval of YEZTUGO, a twice-yearly HIV PrEP injection, which is poised to fortify the company's dominant HIV franchise—a segment that already constitutes over 70% of product sales. This new treatment is expected to significantly cannibalize GSK's APRETUDE and has the potential to become a blockbuster opportunity exceeding $1 billion, while critically extending the franchise's longevity beyond 2037. The stock's current valuation, reflecting an implied -1% revenue decline at stable 32% FCF margins, suggests a valuation disconnect. A successful pivot to even low-to-mid single-digit revenue growth could unlock substantial upside, with analysis suggesting a potential 50% increase at a 4.5% growth rate. While the HIV segment is strengthening, headwinds persist in the Liver Disease and Cell Therapy portfolios, with the latter facing intense competition from Bristol-Myers Squibb's BREYANZI, which saw sales surge over 100% in Q2. However, these challenges are partially offset by positive developments for the oncology drug TRODELVY, which could double its addressable market, and a promising pipeline asset in anito-cel. The company maintains a robust financial profile, generating approximately $8 billion in annual free cash flow with a modest Net Debt/EBITDA of ~1.5x, supporting a sustainable 2.77% dividend and ongoing share buybacks.

Key Decisions for Investors

• Consider the stock's potential for a significant re-rating, as its current valuation appears to price in a pessimistic growth outlook that is directly challenged by the FDA approval and blockbuster potential of YEZTUGO.
• Investors should closely monitor the market penetration and uptake of YEZTUGO against GSK's APRETUDE, as successful execution is the primary catalyst for achieving the mid-single-digit revenue growth required to unlock valuation upside.
• Weigh the strength of the core HIV franchise against persistent headwinds in the Cell Therapy and Liver Disease segments, watching for key pipeline catalysts like the label expansion of TRODELVY to gauge the potential for broader growth.
• Acknowledge the firm's strong financial foundation, including robust free cash flow and a sustainable 2.77% dividend yield, which provides a degree of downside support and income for investors while the growth thesis materializes.